Orphan Drug Status: Are Head-to-head Trials Needed To Show Superior Safety?

CSL Behring petitions FDA to revoke Wilate's orphan drug designation, but Octapharma counters that the effectiveness of its product's dual viral inactivation processes can be seen in post-market reporting.